Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.

From the category archives: OBN News

Funding & Investment

Quotient Sciences Acquires Arcinova, the UK-Based Contract Development and Manufacturing Organization

Feb. 9, 2021 – Quotient Sciences, the drug development and manufacturing accelerator, announced that it has acquired Arcinova, the U.K.-based multiservice contract development and manufacturing organization (CDMO). With over 40 years of experience and 160 employees, Arcinova provides drug substance, drug product and bioanalysis services to over 200 pharma and biotech customers worldwide.

Read the rest of entry »

Vaccitech receives government grant for COVID-19 vaccine research

Oxford, UK: Vaccitech Limited, a clinical-stage biopharmaceutical company developing immunotherapies to treat and prevent infectious diseases and cancer, announces today that it has received a non-dilutive Government grant to support research with its next-generation technology platform to protect against COVID-19. The grant is part of the UKRI-NIHR COVID-19 rapid response rolling call for proposals with potential to deliver public health impacts within 12 months. Preclinical data indicate Vaccitech’s new platform induces leading antibody and cell-mediated immune responses, two arms of the immune system known to protect against disease, when compared with the adenoviral platforms currently in vaccine trials for COVID-19. The preclinical data informed the decision of UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR), and other funders including the World Health Organization (WHO), to support Vaccitech’s research efforts. Vaccitech was awarded £1 ...

Read the rest of entry »

Kent consortium gets green light to develop £60m investment bid to accelerate medicines development

Kent, UK:  A proposal that could bring £60million investment into the life sciences sector in Kent has taken a significant stride forward by securing £50,000 to develop the bid further. The money is seedcorn funding via UK Research and Innovation’s flagship £236m Strength in Places Fund. If the bid is successful, it will provide funding for an ‘Accelerated Medicines Design and Development’ (AMDD) project to be based in Discovery Park, Sandwich. This would build on an existing concentration of research excellence associated with Pfizer and other companies at Discovery Park, alongside a network of partners.   Advanced digital tools are transforming our understanding of disease and the drug discovery process and the AMDD project intends to focus on the potential of digital technology to speed up the ‘development’ phases of work on new medicines.  Developing a medicine is currently a physical laboratory and experiment intensive process, ...

Read the rest of entry »

Discovery Park receives £2.5m of Government funding to accelerate delivery of Incubator

Sandwich, Kent, UK:  Discovery Park, the Life Sciences Opportunity Zone for ambitious and growing life sciences companies, has been awarded £2.5m towards accelerated delivery of its Incubator facility by the South East Local Enterprise Partnership (SELEP). The grant, which comes from SELEP’s £85m share of the Government’s new Getting Building Fund, will be used to create flexible laboratory, write-up and office space for innovative SMEs. Discovery Park’s investors are committing £3m to this development, which is expected to be completed by the middle of next year. A masterplan has been created for the Incubator space and initial design works completed. The 50,000 sq ft of laboratory and write-up space will be created on two floors of the East Block of the Park’s Building 500. The new Incubator facility will be suitable for all types of start-ups and early stage companies, including drug discovery, cell and gene therapy, digital health, manufacturing a ...

Read the rest of entry »

VivoPlex Clinical Stage funding round brings £3.9m for product development

  Oxford, UK:  VivoPlex Group Ltd, which is transforming fertility treatment and women’s health via intra-uterine sensing, has raised £3.9m in its Clinical Stage financing round. The funds, which were raised in two tranches, will be used to complete the first clinical feasibility study of its wireless battery-free uterine sensor system. The study is expected to generate key clinical data to support European approval (CE marking) for the company’s first product.   The Future Fund participated in the second tranche of the fundraising alongside other investors, unlocking matched financing and helping to drive the business forward towards commercialisation. Developed by the Government and delivered by the British Business Bank, the Future Fund supports high potential innovative businesses in the UK currently affected by Covid-19.   In line with other medical device and pharmaceutical companies, the clinical feasibility study will start as soon as practicabl ...

Read the rest of entry »

AMR Action Fund | $1B USD generated

The AMR Action Fund totals approx. $1B USD and has been generated by 23 pharma companies in partnership with the WHO. This fund will focus on treatments for drug resistant infections, a major threat to global health and already responsible for 700,000 deaths per year.

Lloyd Payne PhD, Evotec' s EVP Head of Anti-Infectives Operations, discusses what this funding means for the future of AMR: | [email protected] #researchneverstops #AMR #antimicrobialresistance 

Innovate UK launches the next round of the Biomedical Catalyst - launch on 27th July

£30 Million is available to support industry-led research and development projects that seek to provide solutions to Health and Care challenges.

Read the rest of entry »

Evox Therapeutics Announces a Multi-Target RNA Interference and Antisense Research Collaboration and License Agreement With Lilly

Evox Therapeutics Announces a Multi-Target RNA Interference and Antisense Research Collaboration and License Agreement With Lilly

Evox to use its proprietary exosome loading and CNS-targeting technologies to develop oligonucleotide drugs for the treatment of neurological disorders.

Read the rest of entry »

Five major UK Life Sciences Membership Associations team up to lobby parliament regarding Entrepreneurs’ Relief

OBN, OneNucleus, BioNow, Medilink Midlands and MediWales, major not-for-profit life sciences membership organisations in the UK, which together represent around 2,000 active life sciences companies, have sent an open letter on Friday 22 June to the Chancellor of the Exchequer the Rt Hon Philip Hammond, MP in regard to the recently proposed changes to Entrepreneurs’ Relief.

Read the rest of entry »

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.